Open AccessComorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers
Author(s) -
Yu. N. Belenkov,
О. А. Цветкова,
Е. В. Привалова,
Grin'ko An,
I. S. Ilgisonis,
О. О. Воронкова
Publication year - 2019
Publication title -
kardiologiâ
Language(s) - English
Resource type - Journals
eISSN - 2412-5660
pISSN - 0022-9040
DOI - 10.18087/cardio.2019.6.n458
Subject(s) - copd , medicine , exacerbation , comorbidity , pulmonary disease , cardiology , heart failure , coronary artery disease , disease , pathogenesis , intensive care medicine
Chronic obstructive pulmonary disease (COPD) is the fourth largest cause of worldwide mortality. Presence of comorbidities is registered in 96% of COPD patients. The most important of these are cardiovascular diseases (coronary artery disease, arterial hypertension, chronic heart failure), which contribute to COPD patients’ mortality in every third case. COPD and cardiovascular diseases have common risk factors and pathogenesis mechanisms. Cardioselective beta-blockers reduce morbidity risk and frequency of COPD exacerbation, are effective and safe in treatment of COPD patients.